Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



The effect of stevia sweetener on diabetic nephropathy in rats

Azza Mohamed Marei,Doaa Ismail Mahmoud.




Abstract

Diabetic nephropathy (DN) is considered a clinical syndrome, which is a diabetic kidney disease characterized by increasing blood pressure, albuminuria, and chronic kidney disease. The current study aimed to determine the effect of sweetener (Stevia rebaudiana ) on diabetic nephropathy in a diabetic rat model. Four groups (n=7) of male albino rats (Rattus norvegicus): the control group, diabetic control group (induced streptozotocin intraperitoneally), two diabetic rat groups treated with 2 doses of stevia (200 and 400 mg/kg body weight) for 4 weeks. Biomarkers of nephropathy were measured in plasma and kidneys at the end of the experiment. The levels of plasma glucose, urea, uric acid, creatinine, renal malondialdehyde (MDA), and caspase-3 significantly increased in diabetic rats and levels of insulin, renal catalase, superoxide dismutase, and vascular endothelial growth factor A (VEGF-A) were significantly decreased. After treating the diabetic rats with natural sweetener (stevia), the kidney and plasma biochemical parameters were improved significantly. These results indicated the major role of stevia in diabetic nephropathy.

Key words: Diabetic nephropathy, natural sweetener, Stevia, Streptozotocin.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.